SIRT1 polymorphisms have previously been associated with depressive and anxiety disorders. We aimed at confirming these earlier findings and extending the analyses to seasonal variations in mood and behavior. Three tag single-nucleotide polymorphisms (SNPs) were selected to capture the common variation in the SIRT1 gene. 5910 individuals (with blood sample, diagnostic interview, self-report of on seasonal changes in mood and behavior) were selected from a representative Finnish nationwide population-based sample. Logistic and linear regression models were used to analyze the associations between the SNPs and depressive and anxiety disorders, metabolic syndrome (EGIR criteria) and its components, and health examination measurements, Homeostasis Model Assessments, and diagnoses of type 2 and type 1 diabetes. SIRT1 rs2273773 showed evidence of association with seasonal variation in weight (C-allele, OR = 0.85, 95% CI = 0.76-0.95, p = 0.005). In addition, our study gave further support for the association of SIRT1 gene with depressive disorders (rs3758391) and diastolic blood pressure (rs2273773).
Introduction
Many recent studies have focused on sirtuin 1 (SIRT1) in relation to metabolism, insulin resistance, cancer, and longevity [1] [2] [3] . SIRT1, which is a histone deacetylase, participates through its deacetylase activity for tens of substrates in the coordination of a range of cellular functions, such as cell-division cycle, response to DNA damage, apoptosis, and autophagy. SIRT1 is also a sensor of the cytosolic housekeeping redox reaction of nicotinamide adenine dinucleotide that is measured with the ratio of the oxidized and the reduced forms, and that is changed by glucose deprivation and the metabolic changes under caloric restriction or fasting. There is an earlier report on SIRT1 in metabolic syndrome, where there was no significant association [4] .
So far, genetic variations in SIRT1 have been associated with depressive [5] and anxiety [6] disorders. In an elegant study, both common and rare variations in SIRT1 in humans were found to associate with the increased odds for anxiety disorders at large [6] . The study also demonstrated that in mice SIRT1 increases anxiety by deacetylating the brain-specific helixloop-helix transcription factor, nescient helix loop helix 2 (NHLH2), which increases its activity on the monoamine oxidase A (MAOA) promoter. As the MAOA enzyme degrades serotonin and dopamine, the increased enzyme activity leads to reduced serotonin and dopamine levels in the brain, especially in those regions related to regulation of mood and emotions, and thereby to increased depression and anxiety [7] [8] [9] .
Further, SIRT1 variants have been associated with depressive disorder [5] , but not with bipolar disorder [10] . However, during a depressive episode due to major depressive disorder or bipolar disorder, the mRNA levels of sirtuin isoforms in peripheral white blood cells, are lowered whereas the levels of those mRNAs in a remissive state are equal to those in healthy controls [11] . Here, it is of note that 10-20% of patients with recurrent major depressive disorder and 15-22% of those with bipolar disorder have the seasonal pattern for mood disorder, or seasonal affective disorder [12] .
It appears that not only mood and behavior, but also the components, or risk factors, of the metabolic syndrome of the individual do fluctuate over the year. The increase in metabolic syndrome prevalence is mainly due to the increases in blood pressure and glucose during the winter, and the seasonal variation in metabolic syndrome prevalence associates with insulin resistance being increased from the extent of mild to moderate [13, 14] .
One aim of our current study was to confirm, as far as SIRT1 is concerned, the earlier findings that have demonstrated associations of sirtuins with depressive and anxiety disorders. Another aim of our current study was to extend the exploration of associations of SIRT1 to concern those with the seasonal variations in mood and behavior, metabolic disorder, and relevant health examination measurements. Here, we report associations to seasonal variation in weight, depressive disorders and diastolic blood pressure.
Materials and Methods Subjects
The subjects were selected from the national Health 2000 survey [15] of Finnish population aged 30 years and older (n = 8028) living in mainland Finland that was approved by the ethics committees of the National Public Health Institute and the Helsinki and Uusimaa Hospital District. All participants provided a written informed consent. The selection (n = 5910) included individuals who had given blood samples, taken part to the Munich-Composite International Diagnostic Interview (M-CIDI) [15] and filled in the self-report on seasonal changes in mood and behavior adapted from the Seasonal Pattern Assessment Questionnaire (SPAQ) [16] .
Phenotypes
Depressive disorders (major depressive disorder, dysthymia) and anxiety disorders (panic disorder w/o agoraphobia, generalized anxiety disorder, social phobia, agoraphobia) without hierarchy criteria were assessed using M-CIDI, a valid and reliable instrument for the assessment of depressive, anxiety and alcohol use disorders yielding diagnoses according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) [16] . The controls did not have any diagnosis of mental disorders nor met any sub-threshold criteria as assessed with the M-CIDI.
The participants filled in a questionnaire of lifetime seasonal variations in mood and behavior adapted from SPAQ [17] . The six items of sleep length, social activity, mood, weight, appetite, and energy level were scored from 0 to 3 (none, slight, moderate or marked change) rather than from 0 to 4 (none, slight, moderate, marked or extremely marked change), with the sum or global seasonality score (GSS) then ranging from 0 to 18. The psychometric properties of this modified questionnaire have been reported to be good [18] . In this study, dichotomous variables (no variation, variation) were computed for the six items.
Routine fasting laboratory tests included the concentrations of blood glucose, serum insulin, serum total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. The Homeostasis Model Assessment (HOMA) insulin resistance and beta-cell function indexes were computed. Blood pressure, height, weight, and waist circumference were measured. Body-mass index (BMI) was calculated (as kg per m 2 ).
Diagnosis of type 2 diabetes and that of type 1 diabetes were assessed on the basis of all available data collected for the health examination study (for details of the methods, see http:// www.terveys2000.fi/indexe.html). Using these data, the metabolic syndrome was assessed with the criteria of European Group for the Study of Insulin Resistance (EGIR) modification of World Health Organization (WHO) criteria: diabetics and highest quartile of non-diabetics for fasting glucose were excluded. To fulfill the EGIR criteria for the metabolic syndrome, two of the following needed to be present: Fasting glucose of 6.1 mmol/l, elevated blood pressure (mean of systolic blood pressure measurements of 140 mmHg, or mean of diastolic blood pressure measurements of 90 mmHG, or medication for hypertension), triglycerides of 2.0 mmol/l or HDL of 1.0 mmol/l or lipid-lowering medication, waist circumference of 94 cm for men and that of 80 cm for women.
Gene and SNP selection SIRT1 SNP selection was based on HapMap phase 3 data (http://www.hapmap.org/) and tagging was done using the Tagger program in the Haploview 4.2 software [19] . The linkage disequilibrium (LD) within the gene and 10 kb of their 5' and 3' flanking regions, i.e. 54 kb (chr10:69,304-69,358 kb, NCBI36/hg18 assembly), was used to select tag SNPs capturing most of the genetic variation. The aim was to capture all the SNPs having a minor allele frequency (MAF) of >5% in the European population (CEU and TSI) in the HapMap database. The pairwise r 2 was set to 0.9 in order to select a tag SNP among the SNPs that were in LD. Four out of 19 SIRT1 SNPs fulfilled the criterion, and three SNPs (rs3758391, rs2273773, rs17454621) were successfully included in the genotyping multiplex.
Genotyping
Genomic DNA was isolated from whole blood according to standard procedures. The SNPs were genotyped at the Institute for Molecular Medicine Finland, Technology Centre, University of Helsinki using the MassARRAY iPLEX method (Sequenom, San Diego, CA, USA) [20] , with excellent success (>95%) and accuracy (100%) rates [21] . For quality control purposes, positive (CEPH) and negative water controls were included in each 384-plate. Genotyping was performed blind to phenotypic information. 440 of 5910 individuals were removed due to a high missing genotype rate (i.e. >0.1). The total genotyping rate in the remaining individuals was 0.996. Finally, there were 5470 individuals and three SIRT1 SNPs for the statistical analyses.
Statistical analyses
Statistical analyses were performed using logistic or linear regression and additive genetic model. Unadjusted, age and sex adjusted, and age, sex and BMI adjusted models were calculated using PLINK software v1.07 [22] . The values presented in the text are from the age and sex adjusted models. Haplotype blocks were defined using Haploview software [19] and the confidence interval algorithm. For the continuous phenotypes (GSS, BMI, waist circumference, diastolic and systolic blood pressure, blood glucose, insulin resistance index, beta-cell index, LDL, total cholesterol, HDL, insulin, triglycerides) 10,000 permutations were used to produce empirical p-values in order to relax the assumption of normality. The p-values were corrected for multiple testing with the Bonferroni method by taking into account the number of SNPs and independent phenotypes. After the Bonferroni correction, p-values of <0.0056 are significant for seasonality, p<0.0071 for metabolic syndrome and p<0.0029 for health examination measurements, HOMAs, and diagnoses of type 2 and type 1 diabetes. For replication of the previous findings reported in the literature, i.e. depressive and anxiety disorders, p-values of <0.05 were considered significant. Population stratification was not addressed.
Results
The participants' general characteristics are reported in Table 1 . The study population of 5910 subjects was 55.4% women and had a mean age of 53.1 years (SD = 15.0), BMI of 27.0 (SD = 4.7), GSS of 5.0 (SD = 3.0), blood pressure of 81.7/134.9 (SD = 11.3/21.3). 8.2% had depressive disorder, 5.3% had anxiety disorder, 23.2% had metabolic syndrome (EGIR). Most participants presented seasonal variations in sleep length, social activity, mood and energy level.
Genotype and allele frequencies and the Hardy-Weinberg equilibrium estimates are shown in Table 2 . No haplotype blocks were formed for SIRT1 (Fig 1) . All the SNP association results are shown in S1 Table. SIRT1 rs3758391 T allele showed nominally significant associations with depressive disorders (OR = 1.19, 95% CI of 1.01 to 1.40, p = 0.040, see Table 3 ), metabolic syndrome (OR = 0.88, 95% CI of 0.80 to 0.97, p = 0.01, see Table 3 ), insulin resistance index (beta = -0.26, 95% CI of -0.48 to -0.04, p = 0.019, empirical p = 0.02, see Table 3 ) and blood glucose (beta = -0.05, CI of -0.09 to -0.002, p = 0.04, empirical p = 0.04, Table 3 ). The associations with metabolic syndrome, insulin resistance index and blood glucose did not remain significant after correcting for multiple testing.
The association of SIRT1 rs2273773 with the seasonal variation in weight (OR = 0.85, 95% CI of 0.76 to 0.95, p = 0.005) remained significant after the Bonferroni correction, the C-allele being associated with the decreased odds for the seasonal variation in weight (Table 3) . SIRT1 rs2273773 C allele associated with both high diastolic (beta = 1.06, 95% CI of 0.43 to 1.68, p = 0.001, empirical p-value = 0.001) and systolic blood pressure (beta = 1.23, 95% CI of 0.19 to 2.28, p = 0.02, empirical p-value = 0.02), of which the association with diastolic blood pressure remained significant after the Bonferroni correction, the C-allele having the odds for higher diastolic blood pressure. 
Discussion
Our current results from the population-based health examination study suggested the minor C-allele of synonymous (Leu!Leu) SIRT1 rs2273773 polymorphism to contribute to higher diastolic blood pressure, and to protect from seasonal variation in body weight. However, the SNP showed no evidence of association with BMI or the metabolic syndrome or its components, as assessed with the EGIR modification of WHO criteria. In agreement, CC carriers have previously been reported to have high systolic and diastolic blood pressures in men [23] , and no association with metabolic syndrome in morbidly obese subjects has been found [24] . However, the C-allele (or CC genotype or C carriers) has been reported to be protective against cardiovascular diseases [25] and contribute to higher energy expenditure [26] , a lower BMI [27] , and lower fasting glucose concentrations and body fat ratios in men [23] . Moreover, the T-allele of SIRT1 rs2273773 was seen, as part of two haplotypes of SIRT1, to be associated with schizophrenia but not with bipolar disorder [10] . We were not able to test this association, since these disorders were not assessed with the method used for diagnostic interview in our study. In addition, our study provides further support of the association between SIRT1 (rs3758391) and depressive disorders (major depressive disorder and dysthymia). Our study does not come without limitations. The assessment of the seasonal variations in mood and behavior was based on the self-report only and only limited variables were controlled for in the statistical analysis. On the other hand, there are strengths in our study such as the number of participants enrolled from a nation-wide and representative sample of the adult general population aged 30 years and older, the health examination protocol for the assessment of the metabolic syndrome, the diagnostic interview for the assessment of depressive and anxiety disorders, and the coverage of SIRT1 for the assessment of genetic association.
In conclusion, we found that SIRT1 (rs2273773) accounts for the seasonal variation in body weight. In addition, our study gave further support for the role of SIRT1 in depressive disorders (rs3758391) and diastolic blood pressure (rs2273773). Thus, SIRT1 appears to contribute to seasonal, mood and cardiovascular physiology in humans.
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